(Q28205383)

English

Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses

scientific article (publication date: December 2001)

In more languages

Statements

scholarly article

0 references

Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses (English)

0 references

ulcerative colitis

1 reference

based on heuristic

inferred from title

author name string

W Kruis

1

0 references

S Schreiber

2

0 references

D Theuer

3

0 references

J W Brandes

4

0 references

E Schütz

5

0 references

S Howaldt

6

0 references

B Krakamp

7

0 references

J Hämling

8

0 references

H Mönnikes

9

0 references

I Koop

10

0 references

M Stolte

11

0 references

D Pallant

12

0 references

U Ewald

13

0 references

language of work or name

0 references

publication date

December 2001

0 references

0 references

49

0 references

6

0 references

783-9

0 references

Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728533

29 September 2017

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728533

29 September 2017

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728533

29 September 2017

Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728533

2 June 2018

What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728533

2 June 2018

Renal and urologic complications of inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728533

2 June 2018

Rapid differentiation of glomerular and tubular proteinuria by sodium dodecyl sulfate polyacrylamide gel electrophoresis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728533

2 June 2018

Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728533

2 June 2018

Biopsy studies in ulcerative colitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1728533

27 November 2018

Simplified high-performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine

1 reference

https://pubmed.ncbi.nlm.nih.gov/11709512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day

1 reference

https://pubmed.ncbi.nlm.nih.gov/11709512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11709512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/11709512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months

1 reference

https://pubmed.ncbi.nlm.nih.gov/11709512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28205383&oldid=1520681395"